At Gertrude Biomedical our strategy is focused on modulating key gene 'switches' also known as transcription factors. This approach has the potential to identify novel therapeutics to treat diseases of unmet medical need. 
Gertrude Biomedical is dedicated to developing novel small molecule inhibitors of the SOX18 transcription factor complex, targeting genes that build blood & lymphatic vessels. This approach 'short circuits' the gene programs that promote pathological vessels in disease, providing the potential to treat human diseases that depend on aberrant vasculature for their growth and spread.

Gertrude Biomedical

Tara Karnezis

This department focuses on the research and advancement of pharmaceuticals from initial development through clinical trials.

Drug Development

This department is responsible for setting the strategic direction and overseeing the overall operations of the organization.

Executive Management

This department focuses on coordinating and managing various business and research initiatives.

Gertrude Biomedical

Org chart

Teams

Drug Development

Executive Management

Program Coordination

Offices

Gertrude Biomedical

Org chart

Teams

Drug Development

Executive Management

Program Coordination

Offices

Related companies